Haemonetics Corp. (HAE)
119.93
-4.18
(-3.37%)
USD |
NYSE |
Nov 06, 16:00
119.88
-0.05
(-0.04%)
After-Hours: 20:00
Haemonetics Research and Development Expense (Quarterly) : 17.03M for Sept. 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 17.03M |
| June 30, 2026 | 16.21M |
| March 31, 2026 | 14.41M |
| December 31, 2025 | 14.29M |
| September 30, 2025 | 14.52M |
| June 30, 2025 | 15.58M |
| March 31, 2025 | 15.96M |
| December 31, 2024 | 15.83M |
| September 30, 2024 | 16.53M |
| June 30, 2024 | 14.46M |
| March 31, 2024 | 13.99M |
| December 31, 2023 | 12.92M |
| September 30, 2023 | 12.66M |
| June 30, 2023 | 12.65M |
| March 31, 2023 | 14.59M |
| December 31, 2022 | 12.69M |
| September 30, 2022 | 10.90M |
| June 30, 2022 | 10.90M |
| March 31, 2022 | 13.21M |
| December 31, 2021 | 10.04M |
| September 30, 2021 | 10.85M |
| June 30, 2021 | 12.60M |
| March 31, 2021 | 9.783M |
| December 31, 2020 | 7.503M |
| September 30, 2020 | 6.972M |
| Date | Value |
|---|---|
| June 30, 2020 | 7.431M |
| March 31, 2020 | 8.796M |
| December 31, 2019 | 6.861M |
| September 30, 2019 | 6.867M |
| June 30, 2019 | 7.487M |
| March 31, 2019 | 8.747M |
| December 31, 2018 | 8.978M |
| September 30, 2018 | 8.583M |
| June 30, 2018 | 9.406M |
| March 31, 2018 | 11.09M |
| December 31, 2017 | 8.127M |
| September 30, 2017 | 7.521M |
| June 30, 2017 | 8.193M |
| March 31, 2017 | 9.321M |
| December 31, 2016 | 8.462M |
| September 30, 2016 | 8.336M |
| June 30, 2016 | 11.44M |
| March 31, 2016 | 11.75M |
| December 31, 2015 | 10.94M |
| September 30, 2015 | 11.55M |
| June 30, 2015 | 11.32M |
| March 31, 2015 | 17.22M |
| December 31, 2014 | 10.64M |
| September 30, 2014 | 10.94M |
| June 30, 2014 | 15.38M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Globus Medical, Inc. | 34.53M |
| Abbott Laboratories | 920.00M |
| ICU Medical, Inc. | 21.75M |
| Merit Medical Systems, Inc. | 22.39M |
| Teleflex, Inc. | 42.98M |